Evaluating the protective effect of dapsone on experimental osteoarthritis models induced by MIA in male rats.

This article investigates the therapeutic potential of dapsone, a drug with known anti-inflammatory and antioxidant properties, in managing osteoarthritis (OA) using a rat model induced by monosodium iodoacetate (MIA). The study found that intraperitoneal administration of dapsone at doses of 10 and 20 mg/kg significantly alleviated pain-related behaviors (mechanical allodynia and thermal hyperalgesia), reduced serum levels of pro-inflammatory mediators (TNF-α, IL-1β, and NF-κB), and protected against articular cartilage destruction and chondrocyte loss. These effects were more pronounced than those observed with diclofenac, a standard anti-inflammatory drug. While the precise molecular mechanisms remain to be fully elucidated, dapsone's modulation of inflammatory pathways and oxidative stress suggests its promise as a potential therapeutic agent for OA, though further research, including clinical trials, is needed to confirm its efficacy and safety in humans.